Martin MacKay

Martin W.
MacKay is the founder of Rallybio Corp., founded in 2018, serving as Chairman since 2024.
Dr. MacKay was the founder of Rallybio LLC, founded in 2018, and served as Executive Chairman & Chief Executive Officer from 2018 to 2023.
Current jobs include Chief Executive Officer at Calyx Group Ltd. (Ireland), Chief Executive Officer & Director at Rallybio Holdings LLC, Chairman at Charles River Laboratories International, Inc. starting 2017, Independent Director at Charles River Laboratories, Inc., and Director at Kailera Therapeutics, Inc. starting 2026.
Former jobs include Chief Executive Officer at Vecta Software Corp.
Ltd., Chief Executive Officer at Neverfail, Inc. in 2012, Chief Executive Officer & Director at Neverfail Ltd., Director at Encysive Pharmaceuticals, Inc. in 2008, Operations Director at The Dun & Bradstreet Corp., Director-Business Development at NorthgateArinso, Inc., Independent Director at Springworks Therapeutics, Inc. from 2024 to 2025, Independent Director at 5:01 Acquisition Corp.
from 2020 to 2022, Independent Director at Novo Nordisk A from 2018 to 2025, President-Global Research & Development at AstraZeneca PLC from 2010 to 2013, Global Head-Research & Development at Alexion Pharmaceuticals, Inc. from 2013 to 2017, Vice President-International at VeriSign, Inc., Head-Drug Preformulation & Delivery at BASF Performance Products Ltd. (United Kingdom), Senior Advisor at New Leaf Venture Partners LLC, President at Pfizer (St. Louis), Head-Molecular & Cell Biology at CRI Worldwide LLC in 1995, Principal at PeopleSoft USA, Inc., Principal at Accenture LLC, Head-Drug Preformulation & Delivery at Ciba-Geigy Pharmaceuticals from 1986 to 1995, Principal at Beecham Pharmaceuticals (UK), and Senior Vice President-Worldwide Development at Pfizer Inc. from 1995 to 2010.
Education includes a doctorate from The University of Edinburgh conferred in 1984 and an undergraduate degree from Heriot-Watt University conferred in 1979.